title: Efficacy and Safety of Combined Carboplatin, Paclitaxel, and Bevacizumab for Patients with Advanced Non-squamous Non-small Cell Lung Cancer with Pre-existing Interstitial Lung Disease: A Retrospective Multi-institutional Study.
abstract: OBJECTIVE
  To investigate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab (CPB) combination chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC) with pre-existing interstitial lung disease (ILD).
  
  
  METHODS
  Twenty-five patients with non-squamous NSCLC with ILD who underwent CPB therapy between March 2007 and July 2013 were analyzed for treatment profiles.
  
  
  RESULTS
  The median age was 67 (range=53-79) years and 96% were men. The triplet chemotherapy was repeated for a median of four cycles. The objective response rate was 72% (18/25), the median progression-free survival time was 7.2 months, and the median overall survival time was 8.5 months. The most frequent adverse event of grade 3 or more was neutropenia (72%, 18/25). Chemotherapy-induced acute exacerbation of ILD occurred in 12% of patients.
  
  
  CONCLUSIONS
  CPB therapy may be an effective and feasible regimen even for patients with ILD, although clinicians should be concerned regarding neutropenia and acute exacerbation of ILD.
authors.affiliation: Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama City, Kanagawa, Japan Second Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan yasuyasuyasu29@yahoo.co.jp enomotoy@hama-med.ac.jp.
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Enomoto
authors.affiliation: Division of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan.
authors.forename: Hirotsugu
authors.initials: H
authors.lastname: Kenmotsu
authors.affiliation: Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
authors.forename: Naohiro
authors.initials: N
authors.lastname: Watanabe
authors.affiliation: Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama City, Kanagawa, Japan.
authors.forename: Tomohisa
authors.initials: T
authors.lastname: Baba
authors.affiliation: Division of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan.
authors.forename: Haruyasu
authors.initials: H
authors.lastname: Murakami
authors.affiliation: Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Yoh
authors.affiliation: Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama City, Kanagawa, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Ogura
authors.affiliation: Division of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan.
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Takahashi
authors.affiliation: Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
authors.forename: Koichi
authors.initials: K
authors.lastname: Goto
authors.affiliation: Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama City, Kanagawa, Japan.
authors.forename: Terufumi
authors.initials: T
authors.lastname: Kato
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D012189:Retrospective Studies
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D016190:Carboplatin; D017239:Paclitaxel
keywords: Bevacizumab; acute exacerbation; interstitial lung disease; non-small cell lung cancer